TrialBMC medicine2026

First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC.

Dongmei Ji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.